Although TAGLN is traditionally considered a tumor suppressor in various cancers, our study uncovers elevated TAGLN expression closely associated with adverse clinical parameters, including poor survival, advanced grading, and lymph node metastasis in HNSCC patients. This evidence concerns the gene TAGLN and metastatic malignant neoplasm in the lymph nodes.